Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- Registration Number
- NCT02603809
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Brief Summary
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.
- Detailed Description
Participation in the study is planned to last up to 18 weeks. A single-blind placebo run-in period of 4 to 6 weeks after which participants will be randomized into a double-blind treatment period of 8 weeks and a washout and follow-up period ending with an end-of-study visit approximately 12 weeks after randomization.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1659
-
Signed informed consent prior to any study-mandated procedure
-
No contra-indication to stop (according to label) anti-hypertensive treatment(s) at screening
-
Mild-to-moderate essential hypertension with or without ongoing anti-hypertensive treatment(s):
-- Mean (of 5 measurements) sitting diastolic blood pressure (SiDBP) ≥ 90 to < 110 mmHg measured by office blood pressure measurements (OBPM).
-
Women of childbearing potential must have a negative pregnancy test and use of reliable methods of contraception
- Severe hypertension (grade 3): mean sitting systolic/diastolic BP (SiSBP/SiDBP; measured by OBPM) ≥ 180/110 mmHg, respectively.
- Secondary hypertension
- Known hypertensive retinopathy greater than Keith-Wagener Grade 2
- Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within 12 months prior to randomization
- Unstable angina within 6 months prior to randomization
- Heart failure New York Heart Association class III and IV
- Valvular defects (such as severe aortic or mitral valve disease) and/or hemodynamically relevant rhythm disturbances
- Clinical evidence of cerebrovascular insufficiency or a cerebrovascular accident within 6 months prior to randomization.
- Subjects working night shifts
- Body mass index < 20 kg/m2 or > 40 kg/m2
- Treatment with any medication which may affect BP (e.g., treatment of psychiatric diseases, ophthalmic preparations)
- Treatment with strong cytochrome P450 3A4 (CYP3A4) isoenzyme inhibitors or inducers
- Treatment with guanethidine and/or mineralocorticoid receptor antagonists within 1 month prior to Screening (Visit 1)
- Treatment with another investigational treatment within 1 month prior to Screening (Visit 1)
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Aprocitentan 10 mg Aprocitentan 10 mg After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period. Placebo Placebo After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period. Aprocitentan 5 mg Aprocitentan 5 mg After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period. Aprocitentan 25 mg Aprocitentan 25 mg After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period. Aprocitentan 50 mg Aprocitentan 50 mg After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period. Lisinopril 20 mg Lisinopril 20 mg After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
- Primary Outcome Measures
Name Time Method Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough Baseline (Day 1) and end of double-blind treatment (Day 56) Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.
- Secondary Outcome Measures
Name Time Method Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough Baseline (Day 1) and end of double-blind treatment (Day 56) Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
The absolute change in mean trough sitting systolic blood pressure (SiSBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the systolic blood pressure from the start of treatment.Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure End of double-blind treatment (Day 56) Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The Canadian Hypertension Education Program (CHEP) issued guidelines proposing cut-offs of 85 mmHg for diastolic blood pressure and 135 mmHg for systolic blood pressure specifically focusing on measurement by automated office blood pressure measurement. The number of participants at the end of the 8-week treatment period that had values below the protocol and CHEP cut-off values are reported.
The initial protocol control rates at Week 8 (Day 56) on trough SiDBP are also reported and were defined as a SiDBP of less than 90 mmHg and a SiSBP of less than 140 mmHg.Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure Baseline (Day 1) and end of double-blind treatment (Day 56) Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting diastolic blood pressure (SiDBP) was 10 mmHg or greater-than 10 mmHg.Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure Baseline (Day 1) and end of double-blind treatment (Day 56) Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis.
A participant was a responder if the reduction from baseline in mean trough sitting systolic blood pressure (SiSBP) was 20 mmHg or greater-than 20 mmHg.Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM) Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56) Diastolic and systolic ambulatory blood pressure monitoring was performed over a 24-hour period with the ABPM device (Mobil-o-Graph) set to record diastolic and systolic blood pressure at a pre-defined time. Over a 24-hour period 3 measurements per hour during the day and 2 per hour during the night were made. The blood pressure measurements were derived from the area under the diastolic and systolic blood pressure curves and divided by the time span and averaged.
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM) Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56) Ratio of group mean at trough to group mean at peak was calculated from the diastolic ambulatory blood pressure monitoring performed over a 24-hour period with the ABPM device. The trough (the smallest blood pressure reduction) and the peak (the highest blood pressure reduction) ratio show the extent of blood pressure lowering throughout the 24-hour dosing interval in the group.
The group mean trough (at 20-24 hours) to group mean (at 2-6 hours) peak of diastolic blood pressure were examined to evaluate the extent to which once-daily dosing criteria were met (trough-to-peak values greater than 0.5).
The ratio is positive if there was a decrease in diastolic blood pressure at both the trough and peak times at the end of treatment (Day 55 to Day 56) when compared to baseline (Day -1 to Day 1).
For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.
Trial Locations
- Locations (86)
Appalachian Cardiovascular Associates
🇺🇸Fort Payne, Alabama, United States
Radiant Research Inc
🇺🇸San Antonio, Texas, United States
Warner Family Practice / Radiant Research Inc
🇺🇸Chandler, Arizona, United States
Phoenix Medical Research Institute LLC
🇺🇸Peoria, Arizona, United States
Advanced Arizona Clinical Research
🇺🇸Tucson, Arizona, United States
Noble Clinical Research LLC
🇺🇸Tucson, Arizona, United States
Desert Sun Clinical Research LLc
🇺🇸Tucson, Arizona, United States
Advanced Research Center Inc
🇺🇸Anaheim, California, United States
Med Center
🇺🇸Carmichael, California, United States
John Muir Physician Network Clinical Research Center
🇺🇸Concord, California, United States
Scroll for more (76 remaining)Appalachian Cardiovascular Associates🇺🇸Fort Payne, Alabama, United States